Data Foundry

Drug recalls 2021

Nystatin Oral Suspension — Class II drug recall D-0721-2021

Terminated recall by PAI Holdings, LLC. dba Pharmaceutical Associates Inc, reported 2021-08-18, distributed nationwide. Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.

Recall numberD-0721-2021
Product typeDrug
ClassificationClass II
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmPAI Holdings, LLC. dba Pharmaceutical Associates Inc, Greenville, SC, United States
Recall initiated2021-07-29
Classified2021-08-12
Reported by FDA2021-08-18
Terminated2022-12-02
DistributedNationwide (US)
Reason classescgmp
NDC00121-0868, 00121-0868-00, 00121-0868-02, 00121-0868-05, 00121-0868-16, 00121-0868-40, 00121-0868-50
Expiration dates2022-09-30, 2022-10-31

Product

Nystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, Rx ONLY, packaged in a) 16 fl oz (473 mL) NDC 0121-0868-16; b) 2 fl oz (60 mL) NDC 0121-0868-02; Manufactured by: Pharmaceutical Associates, Inc. Greenville, SC 29605

Reason for recall

Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0721-2021. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.